These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21256862)

  • 21. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bilateral lipomastia in men: a side effect of highly active antiretroviral therapy.
    Deonarain J; Ramdial PK; Singh B
    Int J Surg Pathol; 2008 Apr; 16(2):171-5. PubMed ID: 18417674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients.
    Seminari E; Tinelli C; Minoli L; Sacchi P; Filice G; Zocchetti C; Meneghetti G; Bruno R; Maserati R
    Antivir Ther; 2002 Sep; 7(3):175-80. PubMed ID: 12487384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
    Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
    Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management.
    Hirsch HH; Battegay M
    Infection; 2002 Oct; 30(5):293-8. PubMed ID: 12382089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in leptin serum levels in HIV-infected children receiving highly active antiretroviral therapy.
    Papaevangelou V; Papassotiriou I; Vounatsou M; Chrousos G; Theodoridou M
    Scand J Clin Lab Invest; 2007; 67(3):291-6. PubMed ID: 17454843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors in human immunodeficiency virus/acquired immunodeficiency syndrome patients undergoing antiretroviral therapy in the state of Pernambuco, Brazil: a case-control study.
    Gelenske T; e Farias FA; de Alencar Ximenes RA; de Melo HR; de Albuquerque Mde F; de Carvalho EH; de Medeiros Barros Z; Diniz GT; Filho Dde B
    Metab Syndr Relat Disord; 2010 Jun; 8(3):271-7. PubMed ID: 20158442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
    ter Hofstede HJ; Burger DM; Koopmans PP
    Neth J Med; 2003 Dec; 61(12):393-403. PubMed ID: 15025414
    [No Abstract]   [Full Text] [Related]  

  • 30. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents.
    Dollfus C; Blanche S; Trocme N; Funck-Brentano I; Bonnet F; Levan P
    HIV Med; 2009 May; 10(5):263-8. PubMed ID: 19178590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.
    Boehme RE; Cameron S
    Antivir Ther; 2009; 14(8):1195-208. PubMed ID: 20032550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications.
    Tarr PE; Telenti A
    Antivir Ther; 2007; 12(7):999-1013. PubMed ID: 18018758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelial function is impaired in HIV-infected patients with lipodystrophy.
    Masiá M; Padilla S; García N; Jarrin I; Bernal E; López N; Hernández I; Gutiérrez F
    Antivir Ther; 2010; 15(1):101-10. PubMed ID: 20167996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options.
    Mallewa JE; Wilkins E; Vilar J; Mallewa M; Doran D; Back D; Pirmohamed M
    J Antimicrob Chemother; 2008 Oct; 62(4):648-60. PubMed ID: 18565973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies.
    Wohl DA
    Top HIV Med; 2004; 12(3):89-93. PubMed ID: 15310940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [HIV infection: emerging issues and new challenges].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Control and treatment of HIV-associated lipodystrophy syndrome and related metabolic complications].
    Hansen BR; Haugaard SB; Nielsen JO; Madsbad S; Iversen J; Andersen O
    Ugeskr Laeger; 2003 Oct; 165(44):4218-20. PubMed ID: 14621554
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.